NCT04539821

Brief Summary

The COVID-19 pandemic is exacerbating the challenges faced by Veterans at risk of opioid overdose including Veterans prescribed moderate-to-high dose long-term opioid therapy (LTOT) whose usual treatment resources and coping strategies may be inaccessible. This project combines established VA care components to deploy and evaluate virtual models of care for Veterans on high-risk LTOT to meet the dual challenges of maintaining social distancing and delivery high quality care.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable chronic-pain

Timeline
Completed

Started Oct 2020

Shorter than P25 for not_applicable chronic-pain

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 3, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 7, 2020

Completed
24 days until next milestone

Study Start

First participant enrolled

October 1, 2020

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 12, 2021

Completed
2.8 years until next milestone

Results Posted

Study results publicly available

June 14, 2024

Completed
Last Updated

June 14, 2024

Status Verified

January 1, 2024

Enrollment Period

8 months

First QC Date

September 3, 2020

Results QC Date

June 8, 2022

Last Update Submit

January 24, 2024

Conditions

Keywords

buprenorphine

Outcome Measures

Primary Outcomes (1)

  • The Number of Patients Who Agree to Change in Their Opioid Regimen, Including Buprenorphine Transfer

    Using shared decision-making with Veterans, we will based the measure on clinical reports of patient change in opioid regimen. This would be tapering (reducing opioid dose), discontinuation, or transfer to buprenorphine. Any reduction or change was considered positive for change, even if the patients returned to their initial dose. The number of patients who agree to change their opioid regimen provides a realistic indicator of overall feasibility/acceptability.

    30 days

Secondary Outcomes (1)

  • Number of Participants Retained in Care at End of Study

    60 days

Study Arms (1)

VCPM

OTHER

VCPM is a multi-component intervention consisting of already-established care processes and materials. First, the patient is mailed or emailed (based on their preference) an informational packet prior to intake appointment. Second, using the collaborative medication management model established in VHA,3 the intake appointment is led by the CPS using a standardized intake evaluation. The CPS and physician design a plan presented to the patient. If BUP switch is offered and accepted, the physician completes additional brief evaluations, including a history, medication review, treatment planning, and discussion of other VCPM components, using two-way audio-video visits (with telephone as a back-up).

Other: VCPM

Interventions

VCPMOTHER

VCPM is a multi-component intervention consisting of already-established care processes and materials.

Also known as: Virtual Chronic Pain Management
VCPM

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Eligible participants must currently receive LTOT for chronic pain at 50 mg morphine equivalent daily dose

You may not qualify if:

  • dementia diagnosis or moderate-severe cognitive impairment
  • unstable or severe untreated psychiatric disorder or medical disease that requires hospitalization
  • documentation of suspected controlled substance diversion
  • inability to communicate by phone

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Rocky Mountain Regional VA Medical Center, Aurora, CO

Aurora, Colorado, 80045, United States

Location

VA Connecticut Healthcare System West Haven Campus, West Haven, CT

West Haven, Connecticut, 06516, United States

Location

MeSH Terms

Conditions

Chronic Pain

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Dr. Brent Moore
Organization
VA Connecticut Healthcare System

Study Officials

  • Brent Adams Moore, PhD

    VA Connecticut Healthcare System West Haven Campus, West Haven, CT

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SINGLE GROUP
Model Details: This single-arm feasibility study will be conducted in two VA sites.
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 3, 2020

First Posted

September 7, 2020

Study Start

October 1, 2020

Primary Completion

May 31, 2021

Study Completion

August 12, 2021

Last Updated

June 14, 2024

Results First Posted

June 14, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations